PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2191365
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2191365
The Colorectal Cancer Diagnostics Market reached USD 14.50 billion in 2025 and is projected to grow at an 8.0% CAGR from 2026 to 2035. The market is expected to cross USD 31.30 billion valuation by 2035. Established endoscopy and pathology services operate alongside expanding stool-based and blood-based screening. Non-invasive testing can improve access while preserving the need for procedural confirmation and tissue assessment after positive findings. Commercial demand consequently spans several linked steps in patient care, connecting preliminary screening with more detailed diagnostic and surveillance requirements.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $14.50 Billion |
| Forecast Value | $31.30 Billion |
| CAGR | 8% |
Disease burden, expanded screening eligibility, and AI-assisted detection drive growth. A larger at-risk population supports initial tests, staging, follow-up, and lesion assessment. Screening access has a stronger commercial effect where patients can move efficiently from preliminary findings to colonoscopy, biopsy, pathology, and molecular evaluation. Policy-supported eligibility increases reimbursed orders and referrals, rewarding suppliers with accessible sample collection and established primary-care and payer relationships. AI detection adds software and service opportunities within existing endoscopy suites. As adoption extends into community and ambulatory centers, decision support and workflow integration can generate continuing demand beyond the replacement cycle of core diagnostic hardware.
Across test type, blood-based liquid biopsy is projected to reach USD 3.10 billion by 2035. Scaling requires regulatory access to become routine ordering in primary care, supported by payer coverage and useful clinical performance for patients with precancerous lesions. The category introduces a non-invasive route into screening, but commercial development depends on its integration into established diagnostic pathways. Suppliers need accessible testing that clinicians can order and patients can use within supported care arrangements. This makes adoption a matter of clinical utility and coverage as well as assay availability. The segment's opportunity therefore rests on converting a developing technology into repeatable participation in everyday screening practice.
By end use, hospitals are projected to reach USD 15.65 billion by 2035. Endoscopy suites, oncology services, pathology laboratories, and complex patient pathways concentrate activity in these institutions. Their combination of diagnostic functions supports purchasing across testing modalities and equipment types. Hospitals can connect screening results with procedures and laboratory assessment, making them important to integrated care delivery. Their commercial role reflects more than the provision of an initial test because patients may need several diagnostic steps within a coordinated system. Suppliers serving hospital accounts consequently address both specialized functions and the workflow relationships between imaging, endoscopy, pathology, and cancer services.
The North America colorectal cancer diagnostics market is projected to reach USD 12.00 billion by 2035. Established colonoscopy infrastructure, extensive diagnostic capability, and policy-supported screening sustain demand. Non-invasive approaches add access routes alongside existing procedures, creating referrals rather than eliminating confirmation requirements. In the United States, payer participation and installed capacity for endoscopy, pathology, and molecular testing support the commercial base. Suppliers need to connect testing access with follow-up capacity as screening participation broadens. The regional opportunity therefore combines established procedural systems with newer modalities that can bring additional patients into diagnostic pathways and support continuing surveillance and clinical assessment.
Exact Sciences held over 16.8% market share in 2025. Its stool DNA screening franchise and commercial reach support its position in non-invasive testing. An agreement for exclusive U.S. rights to Freenome's blood-based colorectal cancer screening tests expands participation in a developing category. This approach connects an established screening business with another collection pathway, strengthening exposure to different patient and clinician preferences. The company's commercial position rests on making screening accessible through its franchise and distribution capabilities. Its broader participation in non-invasive approaches also aligns with a market where preliminary testing can increase the need for confirmatory procedures and connected diagnostic services.
Some of the major players in this market are Olympus Corporation, Boston Scientific, Siemens Healthineers, Roche Diagnostics, Abbott, Guardant Health, GE HealthCare, QIAGEN, Danaher, Thermo Fisher Scientific, Sysmex, H.U. Group, DiaCarta, New Day Diagnostics, Phase Scientific International, and Geneoscopy. Equipment, reagents, laboratory systems, molecular testing, and specialized assays create different supplier positions. Olympus connects endoscopy with consumables, service, and AI workflows, while specialists pursue decentralized access and biomarker differentiation. Competition spans complementary stages of care, with clinical validation, reimbursement, and reliable follow-up important to adoption of new testing approaches.